Resources

Ancillare provides through publication of articles, white papers, ebooks, and more.

READ MORE →

Featured

Clinical Kitting: More Than Just Packing Boxes

Featured
Why Investigator Sites Shouldn’t Order Ancillary Supplies

Explore All Insights & Results

ARTICLES →

WHITE PAPERS →

INDUSTRY PUBLICATIONS →
EBOOKS →
Services

Learn what Clinical Trial Supply services we offer, how our services are delivered, and how you can benefit from an Ancillare Partnership.

LEARN MORE →

ANCILLARY SUPPLY CHAIN
MANAGEMENT →

MEDICAL CONSULTING →

FOR SPONSORS →
FOR CROs →
Why Ancillare
Because we
…maintain a therapeutically representative portfolio across all phases and stages
…boast established relationships and on-the-ground expertise across 22 strategic depots
…cover all major geographies, with access to all global clinical trial sites
…provide in-house medical staff and dedicated project managers to consult on every project
…offer our services at scale, allowing sponsors and CROs to realize 30%+ cost savings
A TRUSTED BIOPHARMA PARTNER →

EXPERIENCED LEADERSHIP →

GLOBAL REACH →
THERAPEUTIC & MEDICAL EXPERTISE →
ANCILLARE PROFESSIONAL TEAM →
COMPANY OVERVIEW →

Contact Ancillare

Sponsors, CROs and SMOs, fill out the brief questionnaire and we’ll connect you to our development team.
For general inquiries, please contact info@ancillare.com
  • Should be Empty:
Ancillare
  • Why Ancillare
  • Services
  • Resources
  • Contact
  • Careers
  • News & Events
  • Why Ancillare
  • Services
    • For Sponsors
    • For CROs
    • Proven Biopharma Partner
    • Medical Consulting for Ancillary Supplies
    • Ancillary Supply Management
  • Resources
  • Contact
  • Careers
  • News & Events
M
  • Follow
  • Follow
  • Follow
  • Follow
+1 877.474.5656
  • Why Ancillare
  • Services
    • For Sponsors
    • For CROs
    • Proven Biopharma Partner
    • Medical Consulting for Ancillary Supplies
    • Ancillary Supply Management
  • Resources
  • Contact
  • Careers
  • News & Events

Ancillare Strengthens Global Clinical Trial Supply Chain Leadership with Return of Chad Finney

Oct 9, 2025 | Press Release

HORSHAM, Pa. — October 9, 2025 Ancillare, the global leader in clinical trial ancillary supply chain management, is pleased to announce the return of Chad Finney as Senior Vice President of Business Development.

Finney brings over 15 years of experience in clinical trial supply and healthcare. He returns to Ancillare after serving as Vice President of Global Business Development at Adwin Scientific, Slope, and Orifarm Clinical Trial Supplies (formerly Pilatus Comparator Solutions), where he led strategic growth initiatives and strengthened client partnerships across the life sciences industry.

During his earlier tenure at Ancillare, Finney advanced from Business Development Manager to senior leadership, securing key clients that evolved into long-term strategic partnerships. He has built strong relationships with pharmaceutical and biotechnology companies, and leading CROs worldwide. Learn more about Ancillare’s global solutions.

In his new role, Finney will define and execute Ancillare’s global business development strategy, driving revenue growth, expanding partnerships, and strengthening the company’s global presence.

“We are thrilled to welcome Chad back to Ancillare,” said Joanne Santomauro, CEO. “His deep industry expertise and proven leadership will help us continue to grow and deliver exceptional value to our clients worldwide.”

Finney’s return reinforces Ancillare’s commitment to innovation, operational excellence, and client-focused partnership, solidifying its position as a trusted global partner for ancillary supply chain solutions supporting Sponsors, CROs, and research sites.

The Hidden Cost of Quality in Clinical Trials and Why Choosing the Right Partner Pays Off

The Hidden Cost of Quality in Clinical Trials and Why Choosing the Right Partner Pays Off

Aug 19, 2025 | Articles, Featured

In clinical research, Sponsors are under constant pressure to do more with less. They must cut costs, speed up timelines, and navigate growing regulatory complexity — all while delivering reliable, high-quality results.

At first glance, choosing the lowest-cost provider may seem like a smart move. But time and again, that decision leads to hidden costs, delays, and patient risks. 

The Hidden Cost of Poor Quality in Clinical Trials 

At Ancillare, we’ve seen it firsthand. Sponsors who select vendors based solely on the upfront price often end up spending twice as much correcting quality-related issues, including:

  • Regulatory delays
  • Non-compliant packaging
  • Temperature excursions
  • Missed or late shipments

This mirrors industry-wide findings. The American Society for Quality reports that poor quality can account for 15-40% of total business costs, much of it hidden in rework, delays, and noncompliance. (ASQ, Cost of Quality)

Poor quality in ancillary supply management affects more than logistics.  It creates cascading problems throughout the clinical trial, from protocol deviations to missed shipments. But the most serious risk is to patients. Without oversight from subject matter experts in global regulatory compliance, medical, and quality assurance, there is a real possibility that patients may receive incorrect, delayed, or compromised supplies. These breakdowns can jeopardize patient safety, impact outcomes, and erode trust in the trial itself. The cost is not only financial — it is human.

What Is the Cost of Quality (CoQ) in Clinical Trials?

The Cost of Quality (CoQ) includes all the expenses an organization incurs to achieve and maintain the required level of quality. Understanding CoQ is crucial for Sponsors managing clinical trial supply chains because they extend far beyond simple inspections or compliance checks.

CoQ is traditionally divided into four key categories:

Prevention Costs:
These are investments made to avoid defects before they occur. Examples include staff training, process design and validation, quality planning, and maintaining a strong Quality Management System (QMS). Prevention reduces the likelihood of costly failures downstream.

Appraisal Costs:
These costs involve measuring and monitoring activities such as inspections, audits, and testing. They help detect defects early in the process before they reach clinical sites.

Internal Failure Costs:
These arise from errors identified before delivery, including rework, wasted materials, delays, and additional labor required to fix issues before the product reaches its destination.

External Failure Costs:
These are the most damaging costs incurred when defects are discovered after delivery. They include site dissatisfaction, protocol deviations, regulatory noncompliance, reputational harm, and sometimes financial penalties.

Many Sponsors underestimate these costs since some, especially failure costs, are hidden or indirect. However, failing to invest adequately in prevention and appraisal often leads to greater internal and external failure costs, threatening trial timelines, budgets, and overall trial success.

How Quality Failures Impact Patients and Outcomes

When ancillary supply chains break down, the impact is not only financial. Quality failures can lead to:

  • Missed patient doses
  • Delayed or interrupted care
  • Participation setbacks
  • Compromised trial integrity

Ultimately, the patient bears the consequences of supply chain gaps, making quality not just a compliance issue, but an ethical responsibility.

Why the Right Partner Matters in Ancillary Supply Management 

Quality is not just a checkbox — it’s a critical factor in controlling costs, ensuring compliance, and protecting patients.

Ancillare’s fully integrated model embeds quality and regulatory oversight into every stage of the clinical trial supply chain. Our global Quality Management System (QMS) is designed for the complexity of multinational studies, helping Sponsors avoid costly setbacks.

With centralized oversight and harmonized processes, Ancillare helps Sponsors:

  • Streamline planning and sourcing from the start
  • Ensure compliance in kitting, packaging, and labeling
  • Maintain full traceability during global distribution
  • Meet storage and temperature controls requirements
  • Support reconciliation and reclamation

By combining global infrastructure with deep quality and regulatory expertise, Ancillare prevent errors that compromise clinical trial timelines and patient safety. 

Quality Is a Strategic Investment, Not an Expense

For clinical trial Sponsors, quality is not optional, it is a strategy investment. It protects patients, safeguards timelines, and enhances trial integrity.

At Ancillare, quality is built in from the start; not managed after the fact.  From protocol analysis to site delivery to final reclamation, we reduce complexity and risk while supporting speed, compliance, and cost control.

When evaluating partners, the question is not only what a service costs, but what it could cost if quality is compromised.

Partner with Ancillare for Quality in Clinical Trial Supply Chain Management

Contact Ancillare to discover how we can help you manage your clinical trial ancillary supplies with the quality, oversight, and consistency your trial — and your patients — deserve. 

 

The Hidden Cost of Quality in Clinical Trials and Why Choosing the Right Partner Pays Off

Why Investigator Sites Shouldn’t Order Ancillary Supplies: Uncovering the Hidden Risks that Could Derail Your Clinical Trial

Apr 16, 2025 | Articles

Risks of Investigator-Managed Supplies

Clinical teams in pharma and biotech often look for ways to optimize budgets and streamline operations. One approach that may seem efficient is allowing investigator sites to order their own ancillary supplies for clinical trials. While it may appear to offer greater flexibility and control, this decentralized model introduces hidden risks in clinical trial supply chain management, such as including increased costs, regulatory risks, and operational inefficiencies.

  1. Lack of Standardization

When investigator sites source their own ancillary supplies and equipment, it creates inconsistencies in product quality, regulatory compliance, and compatibility across sites. These discrepancies compromise study integrity and patient safety, which are critical aspects of regulatory compliance in clinical trials.

  1. Higher Costs, Not Savings

It may seem cost-effective to shift ancillary supply management to sites, but it often leads to higher overall expenses due to:

  • Paying higher per-unit costs due to non-bulk purchasing
  • Missing supplier discounts compared to centralized procurement
  • Adding administrative burden on sites

Rush orders alone can cost up to 50% more than standard procurement, according to industry data.  By contrast, centralized procurement strategies use economies of scale and supplier negotiations to lower costs and improve financial efficiency across the clinical trial supply chain.

  1. Regulatory and Compliance Risks

Allowing investigator sites to independently manage ancillary supplies increases the risk of using non-compliant or unvalidated products. This can lead to protocol deviations, audit findings, and delays in regulatory approvals. Effective clinical trial risk management becomes much harder to maintain with decentralized procurement.

Recent FDA Form 483s from 2024 cited sites for poorly maintained equipment, missing calibration records, and failure to follow sponsor protocols.  These issues could have been avoided with centralized quality control. Poor site-level burden management in this area can significantly delay trial timelines.

  1. Logistical and Supply Chain Issues

Centralized procurement streamlines clinical trial logistics, inventory tracking, and supplier accountability. When sites handle purchasing non-IMP supplies, there’s a higher likelihood of stockouts, shipment delays, and supply mismatches, impacting trial timelines and data integrity. A strategic approach to clinical trial solutions ensures that the supply chain runs smoothly, mitigating these risks.

  1. Improper Equipment Management

Most sites lack the resources to handle the full lifecycle of clinical trial equipment, including calibration, maintenance, and end-of-trial disposition. Without centralized oversight from a partner, trials risk delays, noncompliance, and increased costs due to improper equipment management.

  1. Complicated Inventory Management

Effective inventory tracking and replenishment require specialized systems and oversight that many sites lack. Poor inventory management can lead to stock shortages, expired supplies, and inefficiencies that delay trials.

  1. Burden on Investigator Sites

Asking sites to handle procurement adds unnecessary stress to already overburdened staff, increasing the risk of mistakes and delays. This can negatively impact site satisfaction and retention, ultimately hindering the success of your trial.

  1. Negative Impact on Sustainability

When sites independently order ancillary supplies, inefficient ordering, increased packaging waste, excess inventory, and redundant shipments contribute to unnecessary carbon emissions and environmental waste. Centralized procurement allows for optimized shipping, reduced packaging, and better resource allocation, supporting sustainability goals.

  1. Compromised Patient Safety

Improper supply management can directly affect patient safety. Issues like expired products or supply shortages can lead to adverse events or delays in treatment, impacting both patient health and trial integrity.

A Smarter Approach to Ancillary Supply Management

Instead of pushing procurement to individual sites, clinical teams should partner with a full-service provider that manages ancillary supply management from trial start-up through closeout. A global, strategic partner helps sponsors reduce site burden and deliver high-quality, cost-effective solutions for every aspect of the clinical trial supply chain.

A global partner can:

  • Reduce costs through economies of scale and supplier negotiations
  • Ensure regulatory compliance in clinical trials and product standardization
  • Streamline logistics and inventory tracking
  • Manage equipment calibration, maintenance, and reclamation
  • Support sites by allowing them to focus on patient recruitment, enrollment, and care
  • Advance sustainability goals through smarter supply management

Having clinical sites manage their own ancillary supplies, equipment, and medical devices does not optimize your clinical trial supply chain management. In an industry where precision, compliance, and patient safety are critical, decentralized ancillary supply management introduces unnecessary risks and headaches. A dedicated partner ensures streamlined operations, regulatory compliance, and cost efficiency.

Ready to simplify your clinical supply chain and protect your clinical trial’s success? Let’s talk.

References

  1. Counting the Ways Supply Chain Inefficiencies Impact Patient Care, Medical Design & Outsourcing. Read
  2. FDA Form 483 Observations, 2024. U.S. Food and Drug Administration. FDA.gov

 

Ancillare Becomes a Global Distributor of Dexcom G7 Continuous Glucose Monitor (CGM) for Clinical Trials

Feb 4, 2025 | Press Release

HORSHAM, Pa. — February 4, 2025 Ancillare, the global leader in clinical trial supply chain solutions, is excited to announce its new role as a global distributor of the Dexcom G7 Continuous Glucose Monitor (CGM) for clinical trials. This cutting-edge device offers real-time, precise glucose data that will significantly improve study participant compliance, streamline decentralized trials, and reduce errors, making it an invaluable tool for clinical research.

The Dexcom G7 CGM provides accurate, continuous glucose monitoring, allowing healthcare professionals and researchers to access up-to-the-minute insights into participants’ glucose levels. This data enhances study design, increases operational efficiency, and focuses on participant well-being. It ensures that study participants’ glucose numbers are constantly monitored, anytime, anywhere, which is particularly crucial in decentralized and remote trials.

For Sponsors, accuracy and simplicity are paramount. for clinical trials. The Dexcom G7 CGM offers proven accuracy, enabling better -informed treatment decisions. By equipping study participants with this technology, Sponsors can allow participants to manage their diabetes with confidence while optimizing the trial process.

Through Ancillare’s comprehensive clinical trial supply services, Sponsors are supported with significant cost savings, optimize resource allocation, reduce risks, and improve overall coordination throughout the clinical trial supply chain. These capabilities, combined with the advanced technology of the Dexcom G7, ensure a streamlined and efficient clinical trial experience.

For more information about Ancillare and including Dexcom G7 CGM in your clinical trial, visit ancillare.com or contact us.

The first and only Life Sciences company dedicated to Ancillary Supply Chain for clinical research.

Categories

  • Articles
  • Ebooks
  • Featured
  • Industry Publications
  • Press Release
  • White Papers

Recent Posts

  • Ancillare Strengthens Global Clinical Trial Supply Chain Leadership with Return of Chad Finney
  • Ancillary Kitting: More than Just Packing Boxes
  • The Hidden Cost of Quality in Clinical Trials and Why Choosing the Right Partner Pays Off
Ancillare

Americas: +1 877.474.5656

Europe: +31 20899 1756

info@ancillare.com

© 2026 Ancillare, LP. All Rights Reserved.

Privacy Policy | Sitemap

Global Headquarters
700 Enterprise Road
Horsham, PA 19044
United States

Ancillare Americas
717 Dickerson Road
North Wales, PA 19454
United States

Ancillare B.V.
Zijdelweg 5-D
1187 ZM Amstelveen
The Netherlands

  • Follow
  • Follow
  • Follow
×